Cureus has published a new case report on follicular atopic dermatitis (AD) in a patient with dark skin, drawing attention to a phenotype that dermatologists routinely miss on Fitzpatrick IV–VI phototypes.

What does the report cover?

The article centers on a single patient presentation of follicular AD, the variant in which spongiotic inflammation clusters around hair follicles rather than producing the classic flexural plaques most clinicians associate with eczema. In darker phototypes, that follicular accentuation can dominate the clinical picture, mimicking lichen planopilaris, papular eczema, or even follicular psoriasis.

Why does skin tone matter here?

Erythema is muted in melanin-rich skin. The erythema index that drives a bedside diagnosis of AD in a white patient may read as violaceous, gray-brown, or simply as perifollicular accentuation in a Black or brown-skinned patient. A 2017 British Journal of Dermatology review (Nomura, Wu) and the 2019 Allergol Int AD-in-skin-of-color series both flagged this as a driver of delayed diagnosis — and the follicular variant amplifies the problem because follicular papules get mistaken for acne, keratosis pilaris, or follicular lichen planus.

What should clinicians look for?

The reported pattern, drawn from the case description, tracks with prior case series on follicular AD in skin of color:

• Distribution: trunk and extensor surfaces more than antecubital/popliteal fossae
• Lesion type: pinpoint follicular papules, often excoriated, with a rough "goosebump" texture
• Associated signs: prurigo nodularis–like secondary lesions from chronic scratching, post-inflammatory hyperpigmentation rather than the erythema-first pattern seen in lighter skin

That last point matters for scoring. Standard tools — EASI, SCORAD, even the newer ADCT — were validated on predominantly fair-skinned cohorts, and a 2022 JAAD paper by Barrett et al. showed EASI underestimates severity in Fitzpatrick V–VI patients because it weights erythema heavily.

What does this change for the practicing dermatologist?

Three concrete things:

1. Lower your threshold for biopsy when a dark-skinned patient presents with papular, follicular, or "acneiform" eczema that is not responding to standard care. A 4-mm punch from an active follicular papule will often show the spongiotic follicular infundibulum changes that confirm AD.
2. Document pigmentary sequelae explicitly. PIH and pityriasis alba are not cosmetic afterthoughts in these patients; they are the chief complaint and they should appear in the assessment plan, the E/M coding, and the patient counseling.
3. Reconsider step-up therapy. Dupilumab,tralokinumab and JAK inhibitors have all reported subgroup data showing meaningful itch and lesion reduction in patients with skin of color, but enrollment remains skewed. A clear follicular-AD phenotype may make a patient a stronger candidate for systemic therapy earlier than the visual severity score suggests.

The bigger picture

Skin-of-color dermatology has gained roughly a dozen dedicated publications per year since 2020 across JAAD, JID and the British Journal of Dermatology, and case reports like this one fill a specific niche: they put a face and a histopathology slide to presentations that trial cohorts still underrepresent. If the major AD therapeutic trials of the next three years — the lebrikizumab phase 4 program, the upadacitinib pediatric extension, the nemolizumab long-term cohort — enroll proportionally to U.S. and global disease burden in Fitzpatrick V–VI patients, the follicular phenotype will stop being a footnote and start showing up in the endpoint tables.

Until then, a single case report on a frequently misdiagnosed variant is worth more than its evidence level suggests.